 The challenge of developing and optimizing antibody production processes involves balancing product titers, impurity composition, quality demands, complexity, costs, and efficiency while dealing with variations in impurities caused by culture conditions. This requires optimization and adaptation of existing unit operations, assessment of alternative separation technologies, and the search for new methods to address bottlenecks in downstream processing. This article was authored by Petra Grohmeier, Reinhard Ditz, and Johann Strube.